Article
Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes.
Pharmacogenetics and genomics - 1 Apr 2010
Beitelshees Amber L, Finck Brian N, Leone Teresa C, Cresci Sharon, Wu Jun, Province Michael A, Fabbrini Elisa, Kirk Erik, Zineh Issam, Klein Samuel, Spertus John A, Kelly Daniel P
Abstract excerpt
OBJECTIVE: UCP2 -866G>A (rs659366) has been implicated in cardiometabolic disease and represents a novel candidate gene for beta-blocker response, particularly among patients with diabetes. We assessed the function of -866G>A and its role as a modifier of beta-blocker treatment outcomes by diabet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
